A short DNA aptamer that recognizes TNFα and blocks its activity in vitro.

Tumor necrosis factor-alpha (TNFα) is a pivotal component of the cytokine network linked to inflammatory diseases. Protein-based, TNFα inhibitors have proven to be clinically valuable. Here, we report the identification of short, single-stranded DNA aptamers that bind specifically to human TNFα. One such 25-base long aptamer, termed VR11, was shown to inhibit TNFα signaling as measured using NF-κB luciferase reporter assays. This aptamer bound specifically to TNFα with a dissociation constant of 7.0 ± 2.1 nM as measured by surface plasmon resonance (SPR) and showed no binding to TNFβ. Aptamer VR11 was also able to prevent TNFα-induced apoptosis as well as reduce nitric oxide (NO) production in cultured cells for up to 24 h. As well, VR11, which contains a GC rich region, did not raise an immune response when injected intraperitoneally into C57BL/6 mice when compared to a CpG oligodeoxynucleotide (ODN) control, a known TLR9 ligand. These studies suggest that VR11 may represent a simpler, synthetic scaffold than antibodies or protein domains upon which to derive nonimmunogenic oligonucleotide-based inhibitors of TNFα.

[1]  Gary N Parkinson,et al.  The application of DNA and RNA G-quadruplexes to therapeutic medicines. , 2011, Chemical Society reviews.

[2]  P. Bates,et al.  Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding* , 1999, The Journal of Biological Chemistry.

[3]  V. Hornung,et al.  Identification of CpG oligonucleotide sequences with high induction of IFN‐α/β in plasmacytoid dendritic cells , 2001 .

[4]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[5]  D. Hedley,et al.  Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy , 2009, BMC Cancer.

[6]  Gavin W. Collie,et al.  The Application of DNA and RNA G‐Quadruplexes to Therapeutic Medicines , 2012 .

[7]  T. Zhang,et al.  Liposome-anchored vascular endothelial growth factor aptamers. , 1998, Bioconjugate chemistry.

[8]  W. B. van den Berg.  Anti-cytokine therapy in chronic destructive arthritis , 2000, Arthritis research.

[9]  S. Paludan.  Synergistic action of pro‐inflammatory agents: cellular and molecular aspects , 2000, Journal of leukocyte biology.

[10]  C. C. Hardin,et al.  Monovalent cation induced structural transitions in telomeric DNAs: G-DNA folding intermediates. , 1991, Biochemistry.

[11]  M. Broder,et al.  Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. , 2006, Seminars in arthritis and rheumatism.

[12]  S. Klußmann,et al.  Aminomodified nucleobases: functionalized nucleoside triphosphates applicable for SELEX. , 2003, Bioconjugate chemistry.

[13]  V. Hornung,et al.  Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. , 2001, European journal of immunology.

[14]  L. Mazzarella,et al.  Thrombin–aptamer recognition: a revealed ambiguity , 2011, Nucleic acids research.

[15]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics , 2008, Immunological reviews.

[16]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[17]  J. Barciszewski,et al.  Locked nucleic acid aptamers. , 2009, Methods in molecular biology.

[18]  G. Van Assche.  Immunogenicity of anti-TNF antibodies. Has the veil been lifted? , 2010, Gut.

[19]  J. Smolen,et al.  Assessing remission in clinical practice. , 2007, Rheumatology.

[20]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Sarah W. Burge,et al.  Quadruplex DNA: sequence, topology and structure , 2006, Nucleic acids research.

[22]  C. Nathan,et al.  Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. , 1988, Journal of immunology.

[23]  S. Jackson,et al.  Tumour cell killing by tumour necrosis factor: inhibition by anaerobic conditions, free-radical scavengers and inhibitors of arachidonate metabolism. , 1987, Immunology.

[24]  C. C. Hardin,et al.  Cation-dependent transition between the quadruplex and Watson-Crick hairpin forms of d(CGCG3GCG). , 1992, Biochemistry.

[25]  G. Assche.  Immunogenicity of anti-TNF antibodies. Has the veil been lifted? , 2011 .

[26]  A. Krieg,et al.  CpG motifs in bacterial DNA and their immune effects. , 2002, Annual review of immunology.

[27]  E. Vermaas,et al.  Selection of single-stranded DNA molecules that bind and inhibit human thrombin , 1992, Nature.

[28]  R. V. van Vollenhoven.  Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue , 2007, Annals of the rheumatic diseases.

[29]  L. Gold,et al.  High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. , 1995, Biochemistry.

[30]  K. Thompson,et al.  Pharmacokinetics and Biodistribution of Novel Aptamer Compositions , 2004, Pharmaceutical Research.

[31]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[32]  N. Janjić,et al.  Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor. , 1994, Biochemistry.

[33]  C. Mount,et al.  Rheumatoid arthritis market , 2005, Nature Reviews Drug Discovery.

[34]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[35]  J. Steinke,et al.  2. Cytokines and chemokines. , 2003, The Journal of allergy and clinical immunology.

[36]  J. R. Williamson,et al.  G-quartet structures in telomeric DNA. , 1994, Annual review of biophysics and biomolecular structure.

[37]  J. Feigon,et al.  Multistranded DNA structures. , 1999, Current opinion in structural biology.

[38]  P. Berg.  Anti-TNF alpha therapy , 2004 .

[39]  D. Isenberg,et al.  Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. , 2002, Rheumatology.

[40]  R. Vollenhoven.  Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. , 2007 .

[41]  Oleg Kikin,et al.  QGRS Mapper: a web-based server for predicting G-quadruplexes in nucleotide sequences , 2006, Nucleic Acids Res..

[42]  J. Szostak,et al.  In vitro selection of RNA molecules that bind specific ligands , 1990, Nature.

[43]  C. Werning.  [Rheumatoid arthritis]. , 1983, Medizinische Monatsschrift fur Pharmazeuten.

[44]  W. Mcgregor,et al.  Inhibition of DNA Replication and Induction of S Phase Cell Cycle Arrest by G-rich Oligonucleotides* , 2001, The Journal of Biological Chemistry.

[45]  Y. Pommier,et al.  Interaction of Human Nuclear Topoisomerase I with Guanosine Quartet-forming and Guanosine-rich Single-stranded DNA and RNA Oligonucleotides* , 2002, The Journal of Biological Chemistry.

[46]  N. Janjić,et al.  High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[47]  P. Ward,et al.  Protective effects of an aptamer inhibitor of neutrophil elastase in lung inflammatory injury , 1997, Current Biology.

[48]  K. Pfeffer,et al.  The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games , 2005, Immunology.

[49]  A. Tulinsky,et al.  The structure of alpha-thrombin inhibited by a 15-mer single-stranded DNA aptamer. , 1994, The Journal of biological chemistry.

[50]  J. Feigon,et al.  Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[51]  N Bischofberger,et al.  The tertiary structure of a DNA aptamer which binds to and inhibits thrombin determines activity. , 1993, Biochemistry.

[52]  A. Randazzo,et al.  Circular dichroism of quadruplex structures. , 2012, Topics in current chemistry.

[53]  L. Gold,et al.  Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. , 1990, Science.

[54]  David Baltimore,et al.  Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism , 1986, Cell.

[55]  C A Smith,et al.  Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. , 1993, Journal of immunology.

[56]  Michael H Weisman,et al.  New therapies for treatment of rheumatoid arthritis , 2007, The Lancet.